SANUWAVE Health

SANUWAVE Health

SANUWAVE Health was formed in 2005 as a Delaware corporation and began trading publicly through a reverse merger the same year. The company's original promise centered on noninvasive shockwave technology for wound healing and orthopedic regeneration, a pitch that has recurred across multiple rebrands and executive teams under CEOs including Kevin A. Richardson, II, who took the top role in 2022. The underlying wealth source is the public equity and convertible-debt holders who have funded persistent operating losses. Richardson previously ran and sold a similar wound-care entity, Celularity, before returning to lead SANUWAVE. The company markets two principal device lines: UltraMIST for promoting wound healing through ultrasound, and orthoPACE for musculoskeletal and orthopedic applications. Both target the US wound-care market, which the company has described in SEC filings as a multibillion-dollar addressable opportunity. In practice, SANUWAVE's historical revenue has never exceeded single-digit millions in any fiscal year while the accumulated deficit grew above $200 million, per the company's own public financial disclosures. The business operates through a direct sales force in the United States, with sporadic distributor arrangements in Europe and Asia that have not produced material international revenue. Past capital raises have included registered direct offerings and convertible-note structures that diluted common stockholders repeatedly — the company effected a 1-for-400 reverse stock split in 2023 to maintain its Nasdaq listing. As of its latest filings, SANUWAVE operated leanly from Suwanee, Georgia, with a small employee base and no disclosed institutional limited-partner capital or committed fund vehicles. The firm does not function as a family office, does not deploy third-party capital in the conventional allocator sense, and has no adjacent wealth-management, philanthropic, or club-deal structures. It is an operating company that finances its working capital through equity-linked securities sold into the public market. The professional count has consistently stayed below 50 in recent years, per its public disclosures. The structural reality here is a publicly traded development-stage medical-device issuer that has survived not through organic demand but through repeated access to public capital markets and aggressive share-structure adjustments. It is not an investment firm. Anyone querying SANUWAVE for allocation purposes has confused the entity with a capital deployer — this is a company seeking investment, not making it.